singapore-biotech
(2)
Nuevocor
Nuevocor is a Singapore-founded, clinical-stage biotechnology company developing genetic medicines for cardiomyopathies driven by aberrant mechanobiology - the mechanical stresses that damage heart-muscle cells. Spun out of Singapore's A*STAR research agency in 2021, the company built a proprietary discovery engine called PrOSIA (Protein Organ Specific Interactome Analysis) to map the functional root causes of genetic heart disease. Its lead program, NVC-001, is an AAV-based gene therapy for LMNA-related dilated cardiomyopathy, an aggressive inherited heart condition with no targeted treatment. Nuevocor received FDA IND clearance for NVC-001 in June 2025 and has raised roughly US$80.6 million to date, including a US$45 million Series B in May 2025.
Paratus Sciences
Paratus Sciences is a biotechnology company decoding the extreme biology of bats to discover first-in-class medicines. Bats live long, tolerate viruses, resist cancer, control inflammation and thrive on high-sugar diets - traits they evolved over roughly 65 million years. Paratus integrates cell biology, comparative genomics and informatics to translate these adaptations into drug targets for inflammatory and cardiometabolic diseases. Launched in 2023 with a $100M Series A and dual sites in New York and Singapore, its lead program PS-1001 is a first-in-class pan-inflammasome inhibitor.